Login / Signup

Targeting Hedgehog Signaling with Glasdegib in Patients with Refractory Sclerotic Chronic GVHD: A Report of Two Phase I/II Trials.

Eduardo Rodríguez ArbolíCatherine J LeeTeresa Caballero-VelázquezMaria Carmen Martinez MunozClara García-CalderónMaría Reyes Jiménez-LeónMaría Aránzazu Bermúdez-RodríguezLucía López CorralAna TrigueroLynn OnstadMitchell E HorwitzStefanie SarantopoulosStephanie J LeeJosé Antonio Pérez-Simón
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Glasdegib demonstrated promising responses in patients with refractory scGVHD, but tolerability was limited by muscle cramping.
Keyphrases
  • open label
  • cancer therapy
  • allogeneic hematopoietic stem cell transplantation
  • clinical trial
  • randomized controlled trial
  • drug delivery
  • acute lymphoblastic leukemia
  • placebo controlled
  • study protocol